Osteoporosis Drugs Market Size is Estimated to Reach USD 20.53 Billion by 2032, Growing at a CAGR of 4.7%: Emergen Research

A recent market research report reveals promising trends for the global osteoporosis drugs market. According to the Emergen Research, the market was valued at USD 13.06 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.7% during the forecast period.

The increasing prevalence of osteoporosis cases, coupled with the growing geriatric population, is driving the market's revenue growth. Osteoporosis drugs are predominantly prescribed for treating osteoporosis, fractures, and related ailments in elderly and postmenopausal women.

Download Free Sample Report PDF @ https://www.emergenresearch.com/request-sample/2742

Key Market Drivers:
1. Continuous Launch of Effective Drugs: The market is witnessing a surge in the introduction of more sophisticated and effective drugs, administered through various methods such as intravenous injections and oral consumption. This is primarily fueled by the rising incidence of osteoporosis cases globally.

2. Increased Research and Development Investment: Pharmaceutical and biotechnology industries are ramping up their investments in research and development, leading to the emergence of new therapeutic alternatives. Positive clinical trial outcomes are anticipated to drive market growth further.

Market Restraints:

Despite the market's growth trajectory, certain factors restrain its expansion:

1. Drug Side Effects and Patent Expirations: Concerns regarding drug side effects, coupled with patent expirations, pose challenges to market growth. Additionally, regulatory hurdles and the lengthy FDA approval process hinder market expansion.

2. Adverse Reactions and Regulatory Hurdles: The prevalence of adverse effects associated with osteoporosis medications, along with regulatory complexities, presents obstacles to revenue growth.

Segment Insights:

1. Osteoporosis Drugs by Drug Class:
• Dominance of Rank Ligand Inhibitors Segment: Rank ligand inhibitors, which have shown improved patient outcomes, account for the largest market share. These inhibitors, when used in combination with other medications, exhibit synergistic effects, contributing to market growth.

• Fastest Growth for Bisphosphonates Segment: Bisphosphonates, a primary therapy for osteoporosis, are experiencing the fastest growth rate. These drugs not only lower bone loss but also enhance bone density and strength, thereby reducing the risk of fractures.

2. Osteoporosis Drugs by Route of Administration:
• Dominance of Oral Segment: The oral segment dominates the market, attributed to the safety, affordability, and convenience of oral medications. Patient preferences for oral drugs, coupled with advancements in oral delivery technologies, are driving segment growth.

3. Osteoporosis Drugs by End-Use:
• Dominance of Hospital Pharmacies Segment: Hospital pharmacies hold the largest revenue share, supported by an increasing number of patients seeking osteoporosis treatment in hospitals. Government support and partnerships with orthopedic centers are further fueling segment growth.

The global osteoporosis drugs market is fragmented, with large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective products.

Some of the major companies included in the global osteoporosis drugs market report are:
• Novartis AG
• Hoffmann-La Roche Ltd
• Merck KGaA
• AbbVie
• Sun Pharmaceutical Industries Ltd
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Pfizer Inc.
• Lilly
• GSK plc
• Asahi Kasei Corporation
• Reddy's Laboratories Ltd.
• Radius Health, Inc.
• Ipsen Pharma
• Johnson & Johnson Services, Inc.
• Viatris Inc.
• Abiogen Pharma S.p.a.
• Torrent Pharmaceuticals Ltd.
• UCB S.A.
• Bristol-Myers Squibb Company
• Procter & Gamble

Get Detailed Market Segmentation: https://www.emergenresearch.com/industry-report/osteoporosis-drugs-market

Osteoporosis Drugs Latest Industry News
• On August 23, 2021, The Drug Controller General of India (DCGI) granted Enzene Biosciences Ltd. Marketing Authorization (MA) for denosumab, a biosimilar medication intended for the treatment of osteoporosis in adults.
• On January 08, 2021, Theramex has introduced Livogiva to European patients for the first time. The initial launch of this treatment is in Germany, and it will soon be made available in other EU countries, including France, Italy, and Spain. Livogiva presents teriparatide, the sole bone anabolic treatment for osteoporosis, in a new format a pre-filled pen, designed for convenient use by patients at elevated risk of fractures.

Osteoporosis Drugs Market Segment Analysis
For the purpose of this report, Emergen Research has segmented the global osteoporosis drugs market on the basis of drug class, route of administration end-use, and region:

• Drug Class Outlook (Revenue, USD Billion; 2019-2032)
o Bisphosphonates
o Rank Ligand Inhibitors
o Selective estrogen inhibitors modulator
o Parathyroid hormone therapy
o Calcitonin
o Others
• Route of Administration Outlook (Revenue, USD Billion; 2019-2032)
o Oral
o Parenteral

• End-Use Outlook (Revenue, USD Billion; 2019-2032)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
o Others

Request A Customization- https://www.emergenresearch.com/request-for-customization/2742

• Regional Outlook (Revenue, USD Billion; 2019-2032)
o North America
1. U.S.
2. Canada
3. Mexico
o Europe
1. Germany
2. France
3. U.K.
4. Italy
5. Spain
6. Benelux
7. Rest of Europe
o Asia Pacific
1. China
2. India
3. Japan
4. South Korea
5. Rest of APAC
o Latin America
1. Brazil
2. Rest of LATAM
o Middle East & Africa
1. Saudi Arabia
2. UAE
3. South Africa
4. Turkey
5. Rest of MEA

The findings of the report indicate a promising outlook for the global osteoporosis drugs market, with significant growth opportunities on the horizon.

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.